Clinical Trial Update: GALLANT 14 Tesaglitazar vs. Metformin and Fenofibrate [Phase 3]

View source ↗

Summary

A Phase 3 trial (GALLANT 14) evaluating tesaglitazar versus metformin and fenofibrate has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• FENOFIBRATE (Fenofibrate)
• Tesaglitazar (tesaglitazar)
• metformin (metformin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes | Phase 3 | Status: TERMINATED